MAZDA CANADA REPORTS SALES FOR JUNE 2025
JUNE AND Q2 2025 HIGHLIGHTS:
CX-70 and CX-90 both set new benchmarks for June sales, and were up 27.3 percent and 51.6 percent, respectively. In Q2, sales of CX-70 and CX-90 rose by 105.7 percent and 34.2 percent compared to 2024.
CX-30 sales for the quarter were up by 16.6 percent compared to Q2 2024.
Mazda3 had a good showing in June and Q2, finishing the month up 63.5 percent versus June 2024, and gained on the quarter, up 23.0 percent vs Q2 2024.
MX-5 sales in June came through with a 100.8 percent YOY gain, besting June sales for the past 33 years.
Mazda's full-line sales in Q2 were up 19.9 percent and are the best combined Q2 results in the last 15 years.
Mazda Canada Inc. is responsible for the sales and marketing, customer service and parts support of Mazda vehicles in Canada. Headquartered in Richmond Hill, Ontario, Mazda Canada has a nationwide network of 163 dealerships. For additional information, visit Mazda Canada's media website at www.media.mazda.ca.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size pharma companies. SAN ANTONIO, July 3, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that Novotech has been awarded the 2025 Global Company of the Year Award in the biotech contract research organization (CRO) industry for its outstanding achievements in clinical trial innovation, strategic execution, and client-centric delivery. This recognition highlights Novotech's leadership in enabling biotech and small to mid-sized pharma companies to accelerate therapeutic development globally through flexible, high-touch, and technologically advanced clinical trial services. The company stands apart in the global CRO landscape with its strategic emphasis on serving biotech clients, offering tailored clinical trial solutions across all phases of development. The company operates in more than 30 locations and has cultivated deep local insights across key clinical trial hubs, including Australia, South Korea, India, China, and the United States. Its ability to combine global standards with regional excellence makes Novotech a trusted partner for biotech sponsors worldwide. "Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for biotech and small to midsize pharma, Novotech leverages deep therapeutic expertise and regional agility to deliver speed, flexibility, and transformative impact in clinical trials," said Unmesh Lal, vice president, healthcare & life sciences at Frost & Sullivan. With nearly three decades of experience, Novotech has built a robust reputation for delivering high-quality clinical trials at speed. Its integrated service model encompasses regulatory consulting, clinical operations, biometrics, data management, and medical writing, allowing clients to streamline their development pipelines from early phase to post-marketing studies. Through a powerful combination of local knowledge, scientific expertise, and digital capabilities, Novotech continues to enhance trial efficiency, patient recruitment, and regulatory outcomes. Novotech's dedication to advancing clinical research is further reflected in its strategic acquisitions and partnerships. The company's expansions into the United States and Europe marked a significant milestone in building a globally unified platform while preserving its excellence in APAC operations. Novotech's sustained growth trajectory is driven by its deep alignment with sponsors' evolving needs and its commitment to scientific excellence and operational agility. "We're honored by Frost & Sullivan's recognition, which highlights Novotech's strategic focus on delivering regional expertise through a global model to support biotech and mid-size pharma sponsors. It also reflects the strength of our teams in driving operational, scientific, and client delivery excellence worldwide," said Dr. John Moller, chief executive officer, Novotech Novotech's unwavering commitment to client experience strengthens its position in the market. By streamlining service delivery, enabling real-time trial visibility through advanced digital systems, and maintaining continuity across project teams, the company delivers exceptional client satisfaction. Its regionalized, partner-led delivery model and localized expertise ensure regulatory compliance and cultural alignment—key factors that drive trial success in various markets. Frost & Sullivan commends Novotech for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, innovation pipeline, and client-first culture are shaping the future of biotech clinical trials and driving tangible outcomes that matter to patients and sponsors. Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, client satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, client service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Tarini Singh E: [email protected] About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
Cision Canada
5 hours ago
- Cision Canada
World-Leading Breakthrough! Risen Energy's HJT Modules Hit Average 740Wp Mass Production with Record 26.61% Cell Efficiency
NINGBO, China, July 2, 2025 /CNW/ -- A milestone in global heterojunction (HJT) photovoltaic technology! Risen Energy Co., Ltd. (Stock Code: 300118) today announced its self-developed Hyper-ion HJT modules have achieved a groundbreaking 740Wp average mass-production power, setting a new industry efficiency benchmark. With certified cell conversion efficiency of 26.61%, this innovation demonstrates immediate R&D-to-production integration. This breakthrough cements Risen Energy's leadership in high-efficiency PV industrialization. Core Innovations: Patent-Protected Tech & Cost-Performance Revolution Leveraging National Key Research and Developement Program, Risen Energy's proprietary technologies deliver structural optimization and drastic cost reduction while maintaining peak efficiency: Metallization Upgrade: Silver consumption slashed to 5mg/W (↓37.5% vs. TOPCon), driving non-silicon cost reduction via stencil printing. Low CTM Loss Encapsulation: Module CTM (Cell-To-Module) loss minimized to 1.8% with cell breakage-rates under 0.03%, enabling high-yield manufacturing. Dual Advantages: High Energy Yield & Ultra-Low Carbon The 740W Hyper-ion module's -0.24%/°C temperature coefficient and 90% bifaciality delivered 4.09% higher power output than TOPCon at SGS Saudi Arabia's test site. Peak monthly gains hit 6.04% in August, proving its "higher heat, higher yield" reliability. Per 100MW project, this translates to: +3 million kWh annual power generation 2,880 tons CO₂ reduction Carbon footprint as low as 376.5kg eq CO₂/kWc Global Market Momentum As the prime solution for utility-scale, commercial/industrial, and high-temperature projects, Risen Hyper-ion Pro series HJT modules dominate: 9GW+ 2025 HJT-specific tenders in China (led by state-owned giants like China Green Dev./CGN etc.) Expansion to 50+ countries across Middle East/Southeast Asia 6%+ verified energy gain in Saudi/UAE high-irradiation regions, slashing LCOE. Vision from Leadership Dr. Yang Pochuan, Dean of Risen Global PV Research Institute: "We're targeting >27% cell efficiency and 790W+ monocrystalline modules within 3 years. Our perovskite tandem tech will enable 850Wp+ mass production by 2028, advancing the world's net-zero transition with 'China Solutions'. SOURCE Risen Energy Co., Ltd
Cision Canada
6 hours ago
- Cision Canada
Minsud Announces Closing of Over-Subscribed Private Placement
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./ TSX-V: MSR TORONTO, July 2, 2025 /CNW/ - Minsud Resources Corp. (TSXV: MSR) (" Minsud" or the " Company") is pleased to announce that it has closed its previously announced (see news release dated June 4, 2025) non-brokered private placement offering of common shares of the Company (" Common Shares") for total gross proceeds of $848,706, issuing 1,146,900 Common Shares at a price of $0.74 per Common Share (the " Private Placement"). The net proceeds will be used to continue exploring the Chita Valley Project as well as working capital and corporate overhead requirements. No commission or finder's fee was paid in connection with the Private Placement. The Common Shares will be subject to a hold period of four months and a day from their date of issuance. The Private Placement remains subject to final approval from the TSX Venture Exchange (" TSXV"). Under the Private Placement, insiders of the Company subscribed for 566,000 Common Shares. Each subscription under the Private Placement by an insider is considered to be a "related party transaction" of the Company for purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (" MI 61-101") and Section 5.9 – Protection of Minority Securityholders in Special Transactions of the Corporate Finance Manual of the TSXV. In completing the Private Placement, the Company is relying upon exemptions from the formal valuation and minority shareholder approval requirements available under MI 61-101. The Company is exempt from the formal valuation requirement in Section 5.4 of MI 61-101 in reliance on Sections 5.5(a) and (b) of MI 61-101 as the fair market value of the transaction, insofar as it involves interested parties, is not more than the 25% of the Company's market capitalization and no securities of the Company are listed or quoted for trading on prescribed stock exchanges or stock markets. Additionally, the Company is exempt from minority shareholder approval requirement in Section 5.6 of MI 61-101 in reliance on, inter alia, Section 5.7(a) as the fair market value of the transaction, insofar as it involves interested parties, is not more than the 25% of the Company's market capitalization. The Company did not file a material change report 21 days prior to the expected closing date of the Private Placement as the details of the insider's participation in the Private Placement had not been finalized at the time. The securities being offered have not been, nor will they be, registered under the United States Securities Act and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful. Early Warning Reporting Compañía de Tierras Sud Argentino S.A. Compañía de Tierras Sud Argentino S.A. (" CTSA", address: 684 Esmeralda Street, 14th floor, Buenos Aires, Republic of Argentina), an insider and control person of the Company, acquired 351,000 Common Shares under the Private Placement. The 351,000 Common Shares acquired by CTSA represent 0.21% of the 166,095,415 Common Shares following the closing of the Private Placement. Prior to the Private Placement, CTSA held 44,773,743 Common Shares, representing 27.14% of the outstanding Common Shares, based upon 164,948,515 Common Shares being outstanding immediately prior to the closing of the Private Placement. CTSA now owns 45,124,743 Common Shares, representing 27.17% of the outstanding Common Shares on an undiluted basis, based upon 166,095,415 being outstanding following the closing of the Private Placement. CTSA does not own any convertible securities of the Company. CTSA acquired and intends to hold the securities for investment purposes. CTSA, depending on market and other conditions, may increase its beneficial ownership, control or direction over the Common Shares or other securities of Minsud through market transactions, private agreements, treasury issuances, exercise of convertible securities or otherwise, in accordance with applicable securities regulations. Depending on market or other conditions, CTSA may sell all or a portion of the Common Shares. An early warning report with additional information with respect to CTSA will be filed on SEDAR+ at copies of which may be obtained by contacting the persons listed below. Carlos Adamo Mr. Carlos Adamo (address: Carlos Pellegrini 1427, 3rd floor, Ciudad de Buenos Aires, Republic of Argentina) an insider of the Company, acquired 165,000 Common Shares under the Private Placement. The 165,000 Common Shares acquired by Mr. Adamo represent 0.09% of the 166,095,415 Common Shares outstanding following the closing of the Private Placement. Prior to the Private Placement, Mr. Adamo held 18,993,712 Common Shares, and stock options (the " Options") exercisable to acquire 1,575,000 Common Shares, representing 11.51% of the outstanding Common Shares on an undiluted basis and 12.35% on a partially diluted basis (assuming the exercise of the Options), based upon 164,948,515 Common Shares being outstanding immediately prior to the closing of the Private Placement. Mr. Adamo now owns 19,158,712 Common Shares, and stock options (the " Options") exercisable to acquire 1,575,000 Common Shares, representing 11.53% of the outstanding Common Shares on an undiluted basis and 12.37% on a partially diluted basis (assuming the exercise of the Options), based upon 166,095,415 Common Shares being outstanding following the closing of the Private Placement. Mr. Adamo acquired and intends to hold the securities for investment purposes. Mr. Adamo depending on market and other conditions, may increase its beneficial ownership, control or direction over the Common Shares or other securities of Minsud through market transactions, private agreements, treasury issuances, exercise of convertible securities or otherwise, in accordance with applicable securities regulations. Depending on market or other conditions, Mr. Adamo may sell all or a portion of the Common Shares. An early warning report with additional information with respect to Mr. Adamo will be filed on SEDAR+ at copies of which may be obtained by contacting the persons listed below. About Minsud Resources Corp. Minsud is a mineral exploration company focused on exploring its flagship Chita Valley Cu-Mo-Au-Ag-Pb-Zn Project, in the Province of San Juan, Argentina. The Company's shares are listed on the TSX-V under the trading symbol "MSR", and on the OTCQX under the symbol "MDSQF". CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain information that may constitute forward-looking information under applicable Canadian securities laws. Forward-looking information includes, but is not limited to, strategic plans, spending commitments, future operations, future work programs, and statements regarding the Private Placement, including the use of proceeds raised thereunder and TSXV approval. Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information including, but not limited to: changes in national and local government, legislation, taxation, controls, regulations and political or economic developments in Canada and Argentina or other countries in which the Company may carry on business in the future; operating or technical difficulties in connection with exploration and development activities; fluctuations in the currency markets (such as the Canadian dollar, Argentina peso, and the U.S. dollar); risks and hazards associated with the business of mineral exploration and development (including environmental hazards or industrial accidents); risks relating to the credit worthiness or financial condition of suppliers and other parties with whom the Company does business; presence of laws and regulations that may impose restrictions on mining, including those currently enacted in Argentina; employee relations; relationships with and claims by local communities; availability and increasing costs associated with operational inputs and labour; the speculative nature of mineral exploration and development, including the risks of obtaining necessary licenses, permits and approvals from government authorities; business opportunities that may be presented to, or pursued by, the Company; challenges to, or difficulty in maintaining, the Company's title to properties; risks relating to the Company's ability to raise funds; fluctuations in commodity prices and the factors identified in the Company's continuous disclosure documents filed on SEDAR+. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking-information contained in this news release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
